cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Search
The power of our people
Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
Generalized pustular psoriasis (GPP): a chronic inflammatory disease
Learn more about this chronic inflammatory disease associated with skin and systemic symptoms
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
World Water Day: Good Health Hinges on Good Water
Clean, safe and accessible water is the most basic prerequisite for life and health
digital_leader_award_2020
Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
Five facts everyone should know about heartworms
Heartworms are dangerous parasites that can infest pets through mosquito bites, causing serious illness. Here are five key facts we all should know about heartworms.
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
empa-reg-outcome-recurrent-events
EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
BTD for GlyT1 in Schizophrenia
Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Company Culture
Company Culture
A guide to hidradenitis suppurativa (HS)
Hidradenitis suppurativa (HS) is a long-term, inflammatory, recurrent, skin condition that causes painful inflamed nodules, or abscesses on the skin
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Combatting Appetite Loss
Discover tips on how to combat appetite loss from Taking Cancer On Through Flavour
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Dedifferentiated liposarcoma: Life with an ultra rare cancer
For Dan, being diagnosed with dedifferentiated liposarcoma, an ultra rare sarcoma, was life changing, and means he now makes the most of every day.
Meet our team
Meet our team
vet scholars symposium
Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
Perceived burden of COPD is higher for younger patients
New global survey reveals perceived burden of disease is greater in younger people living with COPD
Supply Chain Scholarship for Cowtribe
A supply chain course we sponsored boosted the career of Latifa Saaka
Eyes on Retina. The Podcast
Hear from experts and people living with retinal diseases such as wet age-related macular degeneration (AMD), stargardt disease and diabetic retinopathy.
Respimat re-usable wins Pharmapack Eco-Design Award
The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.